OncoTargets and Therapy (Jan 2023)
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
Abstract
Dylan M Buller,1,* Maria Antony,2,* Benjamin T Ristau1 1Division of Urology, UConn Health, Farmington, CT, USA; 2University of Connecticut School of Medicine, Farmington, CT, USA*These authors contributed equally to this workCorrespondence: Benjamin T Ristau, Division of Urology, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030, Tel +1 860 679 3438, Fax +1 860 679 6109, Email [email protected]: Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.Keywords: renal cell carcinoma, adjuvant therapy, targeted therapy, immunotherapy, radiation
